Martin Tolar

Company: Alzheon

Job title: Founder, President & Chief Executive Officer


ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease 4:00 pm

Highlighting the benefits of applying genomic stratification of patients for validation of biomarkers from target discovery to therapeutic development Describing discovery of a novel molecular mechanism of action of ALZ- 801, which blocks formation of toxic amyloid oligomers associated with development and progression of Alzheimer’s disease Reviewing development of ALZ-801, a Phase 3, first-in-class, small…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.